HUTCHMED (China) Ltd
fruquintinib
renal cell carcinoma
Resolved
505days ago
Phase 3 readout · Feb 17, 2025
What's at stake
Phase 3 trial results for fruquintinib in renal cell carcinoma are due Feb 17, 2025. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 13h ago
“As of the PFS final analysis cutoff of February 17, 2025, the median follow-up was 16.6 months.”